Nanexa AB (FRA:40M) PEG Ratio: N/A (As of Jul. 04, 2026)


FRA:40M Nanexa AB FRA:40M
48 GF Score
Price €0.31
GF Value €0.17
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Nanexa AB PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Nanexa AB's PE Ratio without NRI is 0.00. Nanexa AB's 5-Year EBITDA growth rate is 0.00%. Therefore, Nanexa AB's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Nanexa AB's PEG Ratio or its related term are showing as below:



FRA:40M's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.71
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Nanexa AB  (FRA:40M) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Nanexa AB PEG Ratio Related Terms


Nanexa AB PEG Ratio Historical Data

* Premium members only.

The historical data trend for Nanexa AB's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanexa AB PEG Ratio Chart

Nanexa AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nanexa AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:40M vs ZTS, UTHR: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanexa AB PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Nanexa AB's PEG Ratio falls into.


FRA:40M
48GF Score
Nanexa AB FRA:40M
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanexa AB PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Nanexa AB's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Nanexa AB (FRA:40M) Overvalued in 2026?

Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued. The current stock price of €0.31 is trading 81.5% above its estimated GF Value™ of €0.17. GuruFocus considers Nanexa AB to be Significantly Overvalued.

Key valuation signals for FRA:40M:

  • PEG Ratio: N/A
  • GF Value™: €0.17 vs. price of €0.31 (81.5% above fair value)
  • GF Score™: 48/100 with 2 warning signs

No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nanexa AB Business Description

Other Exchanges NANEXA:Sweden
Address Virdings Alle 32B, Uppsala, SWE, 75450
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
48GF Score

Get the complete analysis for FRA:40M

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.31
Price
€0.17
GF Value